Gyre Therapeutics, Inc. GYRE

What this company does

Gyre Therapeutics, Inc. is a commercial-stage biopharmaceutical company that develops and commercializes small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases, operating through its majority indirectly owned subsidiary, Gyre Pharmaceuticals, in the PRC, and through its U.S. operations headquartered in San Diego, California. In the PRC, it markets ETUARY® (pirfenidone) and Etorel® (nintedanib) for idiopathic pulmonary fibrosis, and Contiva® (avatrombopag) for hematologic conditions associated with chronic liver disease. Its pipeline includes F351 (Hydronidone), the company's lead product candidate for liver fibrosis. As of December 31, 2025, it had 618 total employees in the PRC, including 172 in Beijing, 43 in Cangzhou and 403 in other regions. As of December 31, 2025, it had seven full-time employees in the United States. It commenced operations in 2002 as a Delaware corporation, merged with Targacept, Inc. in 2015, and completed a business combination in 2023 to acquire an indirect controlling interest in Gyre Pharmaceuticals, becoming Gyre Therapeutics, Inc.

Written from the business description in GYRE THERAPEUTICS, INC.'s annual report to the U.S. Securities and Exchange Commission, filed 13 March 2026. Every sentence was checked against that document before publication.